Drugs / PF-06840003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02764151 | Sep 2016 → Dec 2018 | astrocytoma (excluding glioblastoma), oligodendroglioma | Pfizer | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-06840003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02764151 ↗ |
| Known as | EOS200271 | “Here, we report the identification and characterization of the novel selective, orally bioavailable IDO1 inhibitor EOS200271/PF-06840003.” PMID 30232146 ↗ Sep 2018 |
| Modality | Small molecule | — CHEMBL4086143 ↗ |
| Route | Oral | “Patients (N = 17) received oral PF-06840003 in four dose-escalation groups” PMID 32436060 ↗ May 2020 |